Drug Trial Radar · NCT05150340
A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)
Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jan 24, 2022
Primary completion
Aug 28, 2023
Study completion Aug 28, 2023
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of the study is to check how much TAK-771 stays in their blood over time, side effect from the study treatment or TAK-771, how much TAK-771 participants can receive without getting side effects from it, and if TAK-771 improves symptoms of primary immunodeficiency diseases (PID). This will help the study sponsor (Takeda) to work out the best dose to give people in the future. The participants will be treated with TAK-771 for totally 27 or 30 weeks. Treatment period is consist of two periods called Epoch 1 and Epoch 2. In Epoch 1, different groups of participants will receive lower to higher doses of TAK-771 for 3 to 6 weeks. The study doctors will check for side effects from each dose of TAK-771. In Epoch 2, participants will receive TAK-771 once a 3 or 4 weeks until the end of 24 weeks. There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug (every 3, or 4 weeks).
Conditions
- Primary Immunodeficiency Diseases (PID)
Interventions
TAK-771Drug
Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Epoch 2: Serum Trough Levels of Total IgG Antibodies After Administration of TAK-771Time frame: Up to Week 31 for Participants with 4-Week Dosing Interval or Up to Week 28 for Participants with 3-Week Dosing Interval
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Kyushu University Hospital
Fukuoka, Japan
Gifu University Hospital
Gifu, Japan
Hiroshima University Hospital
Hiroshima, Japan
Saitama Prefectual Children's Medical Center
Saitama, Japan
Shizuoka Childrens Hospital
Shizuoka, Japan
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
Hospital of University of Occupational and Environmental Health
Kitakyushu, Fukuoka, Japan
Kurume University Hospital
Kurume, Fukuoka, Japan
Kanagawa Children's Medical Center
Yokohama, Kanagawa, Japan
Shinshu University Hospital
Matsumoto, Nagano, Japan
Tokyo Medical Dental University Hospital
Bunkyo-ku, Tokyo, Japan
National Center for Child Health and development
Setagaya-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.